Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patheon Q1 loss narrows
The company reported revenues of $147.2 million for the first quarter ended January 31, 2009, a decrease of 10.4%, compared to $164.2 million for the corresponding period of
The company reported revenues of $147.2 million for the first quarter ended January 31, 2009, a decrease of 10.4%, compared to $164.2 million for the corresponding period of
In his new role, Mr Kandera will be responsible for the global finance function and investor relations of Intercell. Mr Kandera is currently CFO of Intercell’s US subsidiary
Savella (milnacipran HCl), was approved by the FDA on January 14, 2009 and was originally expected to be available in March 2009. The companies submitted a minor post-approval
“In 2008, we put an experienced staff in place to establish the company as a market leader in personalized healthcare and focus our business strategy on increasing revenue
Mr Fan will report to Jinan Song, the company’s chairman and CEO, and will be responsible for all aspects of China-Biotics’s finance functions, including accounting, financial planning, tax,
According to Medicsight, the ColonCAD API 4.0 software is designed to assist radiologists in the detection of colorectal polyps in computed tomography (CT) colonography image data. Version 4.0
According to the company, AN2898 ointment was very well tolerated and demonstrated no irritant potential in the trial. In this cumulative irritation trial, AN2898 ointment at 5% and
Depomed, a specialty pharmaceutical company, has reported net loss applicable to common stock shareholders of $11.23m, or $0.22 diluted net loss per common share for the fourth quarter
Correspondents say the reversal of US policy is part of President Obama’s pledge to make clear that his administration wants scientific research to be free from political interference.
The previous Administration allowed the National Institutes of Health (NIH) to fund human embryonic stem cell research on cell lines created before an arbitrary date, August 9, 2001,